Advanced Solid Tumor
Conditions
Brief summary
A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.
Interventions
DRUGZX-4081
Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Sponsors
Nanjing Zenshine Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Metastatic or locally advanced solid tumor malignancies (breast cancer, urothelial cancer, ovarian cancer, melanoma, NSCLC, renal cell carcinoma, squamous cell cancer of the head and neck, colorectal cancer, and hepatocellular carcinoma) that has progressed on, is refractory to, intolerant to, or for which there is no curative standard of care therapy. 2. Measurable disease with at least 1 lesion amenable to response assessment per RECIST 1.1. 3. Demonstrate adequate organ function. All screening laboratories should be performed within 14 days of treatment initiation. 4. Has a performance status of 0-2 on the ECOG Performance Scale. 5. Life expectancy \>12 weeks at baseline. 6. Women of childbearing potential must have negative serum or urine pregnancy test within 72 hours prior to receiving the first study drug administration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Women of childbearing potential must be willing to use an adequate method of contraception from 30 days prior to the first study drug administration and 120 days following last day study drug administration. 7. Male patients of childbearing potential must be surgically sterile, or must agree to use adequate method of contraception during the study and at least 120 days following the last day of study drug administration. 8. Age ≥18 years at screening. 9. Able and willing to provide written informed consent and to follow study instructions.
Exclusion criteria
1. Patient has disease that is suitable for therapy administered with curative intent. 2. Untreated or uncontrolled central nervous system (CNS) involvement. 3. Any concurrent or recent use (within 28 days or 5 half-lives, whichever is longer) of chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment. 4. Unresolved toxicities from prior therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, with exception of alopecia and vitiligo. 5. Systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent. 6. Patient has an active infection requiring systemic therapy. 7. Patients who have known active HIV, Hepatitis or active COVID-19 infection. (Patients who have been vaccinated against Hepatitis B and who are positive only for the Hepatitis B surface antibody are permitted to participate in the study). Patients who are positive for hepatitis B or C virus must be tested for and have an undetectable viral load. 8. Patients with unstable/inadequate cardiac function: 1. New York Heart Association Class 3 or 4 congestive heart failure, 2. Uncontrolled hypertension, 3. Acute coronary syndrome within 6 months, 4. Clinical important cardiac arrhythmia, 5. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>470 milliseconds (ms) (CTCAE grade 1) using Fredericia's QT correction formula. 9. A history of additional risk factors for Torsades de Pointes(TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome). 10. The use of concomitant medications that prolong the QT/QTc interval. 11. Concomitant use or recent use (at least 2 weeks before the start of ZX-4081 treatment) of drugs that are known to be strong CYP3A4/5 inhibitors and CYP3A4/5 inducers (See 5.4.2 for a list of study medications not allowed during this study). 12. Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following: CYP2C9, CYP2C19, CYP2C8, CYP2D6 and CYP3A4 (See 5.4.2 for a list of study medications not allowed during this study). 13. Concomitant use of drugs that are sensitive substrates with narrow therapeutic index for one of the following transporters: P-glycoprotein (P-gp) and Breast Cancer resistance Protein (BCRP). 14. Recent use a proton pump inhibitor (within 4 days prior to the start ZX-4081 treatment) or a histamine H2 blocker (within 2 days prior to the start of ZX-4081 treatment). 15. Uncontrolled concurrent illness. 16. Patient has concurrent active malignancy other than nonmelanoma skin cancer, carcinoma in situ of the cervix, or superficial bladder cancer who has undergone potentially curative therapy with no evidence of disease. Patients with other previous malignancies are eligible if disease-free for \>2 years. 17. Participation in another clinical trial of an investigational agent within 30 days of screening. 18. Patient has known psychiatric, substance abuse or other disorders that would interfere with cooperation with the requirements of the trial, in the opinion of the investigator. 19. Patients who are pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 30 days after the last dose of trial treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the recommended Phase 2 dose (RP2D) of ZX-4081 | At the end of Cycle 1 (each cycle is 28 days) | To assess number of patients experiencing dose-limiting toxicities (DLTs) in the dose escalation phase |
| Safety and tolerability of ZX-4081 | From first dose of ZX-4081 through 28 days after the last ZX-4081 treatment (up to 2 years); each cycle is 28 days | To examine the incidence of clinical and laboratory adverse events after multiple doses of ZX-4081 in the dose escalation and dose expansion phases |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Half-life of ZX-4081 | Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days) | To evaluate the half-life of ZX-4081 after single and repeated oral, BID doses of ZX-4081 |
| Objective response rate (ORR) | Up to 2 years | To evaluate the objective response rate (ORR) as determined by the specific disease response criteria |
| Duration of Response (DOR) | Up to 2 years | To examine the duration of response (DoR), defined as time from the date of first documentation of response to the date of the first documentation of progressive disease (PD), or death due to any cause |
| Peak Plasma Concentration of ZX-4081 | Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days) | To evaluate the maximum observed concentration (Cmax) after single and repeated oral, twice daily (BID) doses of ZX-4081 |
| Overall Survival (OS) | Up to 2 years | To examine the overall survival (OS), defined as time from the date of first dose of study treatment to death due to any cause |
| Peripheral myeloid-derived suppressor cell (MDSC) proportion in the blood | Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days) | To assess the changes of peripheral MDSC proportion in the blood after single and repeated oral, BID doses of ZX-4081 |
| T cell composition and activation status | Cycle 1 Day1 , Cycle 2 Day 1, and Cycle 3 Day 1 (each cycle is 28 days) | To assess the impact on T cell profiles after repeated oral, BID doses of ZX-4081 |
| Progression Free Survival (PFS) | Up to 2 years | To examine the the progression free survival (PFS), defined as time from the date of first dose of study treatment to the first date of documentation of PD, or death due to any cause |
| Area under the plasma concentration of ZX-4081 | Days 1, 8, and 15 of Cycle 1 (each cycle is 28 days) | To evaluate the area under the curve (AUC) plasma-concentration after single and repeated oral, BID doses of ZX-4081 |
Countries
United States
Contacts
Primary ContactXiaoli Qin, PhD
Backup ContactEdgar Bautista
Outcome results
None listed